{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:54:56Z","timestamp":1769709296155,"version":"3.49.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jpet.2025.103785","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T07:43:30Z","timestamp":1766043810000},"page":"103785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cLetter to the Editor: Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation\u201d"],"prefix":"10.1016","volume":"393","author":[{"given":"Parth","family":"Aphale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shashank","family":"Dokania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Himanshu","family":"Shekhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jpet.2025.103785_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103652","article-title":"Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation","volume":"392","author":"Kaneko","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jpet.2025.103785_bib2","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jacc.2017.07.758","article-title":"Left atrial fibrosis and risk of cerebrovascular and cardiovascular events in patients with atrial fibrillation","volume":"70","author":"King","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103785_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1517\/14656566.7.12.1583","article-title":"Pharmacogenetics of antiarrhythmic therapy","volume":"7","author":"Darbar","year":"2006","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.jpet.2025.103785_bib4","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jpet.2025.103785_bib5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacc.2010.07.046","article-title":"A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation","volume":"57","author":"Camm","year":"2011","journal-title":"J Am Coll Cardiol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:04:04Z","timestamp":1769673844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0022356525402985"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103785","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cLetter to the Editor: Pharmacological study of the safety, efficacy, and potential of M201-A on paroxysmal and persistent atrial fibrillation\u201d","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103652","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103785"}}